ABG
ASND icon

Ally Bridge Group’s Ascendis Pharma A/S ASND Stock Holding History

Ally Bridge Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,080
Closed -$10.2M – 21
2025
Q3 		$10.2M Buy
+51,080
New +$9.53M 6.18% 6

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ally Bridge Group's ASND Position: Q4 2025 in Review

Ally Bridge Group sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 51,080 shares — an estimated $10.2M sold.

Ally Bridge Group first reported a position in ASND in Q3 2025 and held it in 1 quarter. The position peaked at $10.2M in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Ally Bridge Group reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Ally Bridge Group sold 51,080 Ascendis Pharma A/S shares in Q4 2025, an estimated $10.2M.
  • Ally Bridge Group first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 1 quarter.
  • Ally Bridge Group's Ascendis Pharma A/S position peaked at $10.2M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.